Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04454411 · ClinicalTrials.gov registry record · Phase 2
Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder
A Phase 2 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04454411: Clinical Trial Phase 2 study, sponsored by University of Pennsylvania.
NCT04454411 is a Phase 2 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04454411, a Phase 2 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study will investigate the mechanisms of cognitive-behavioral response to medications used for relapse prevention in opioid use disorder (opioid addiction, OUD), through investigation of the neural circuits underlying key cognition functions. The study will use previously validated cognitive probes, functional Magnetic Resonance Imaging (fMRI), and novel extended-release injectable preparations of opioid partial agonist buprenorphine and antagonist naltrexone, in OUD patients to explain the individual heterogeneity of OUD treatment response.
Interventions
- DRUG Vivitrol
- DRUG Brixadi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2024-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04454411
The ClinicalTrials.gov registry entry for NCT04454411 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vivitrol is the first listed.
NCT04454411 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04454411 about?
NCT04454411 is a clinical study titled "Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder". This study will investigate the mechanisms of cognitive-behavioral response to medications used for relapse prevention in opioid use disorder (opioid addiction, OUD), through investigation of the neural circuits underlying key cognition functions. The study will use previously validated cognitive pr...
What is the current status of trial NCT04454411?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2022-08-01. Estimated completion is 2024-08-31.
What interventions are being tested in trial NCT04454411?
The interventions under investigation include: Vivitrol (DRUG), Brixadi (DRUG).
Who is sponsoring clinical trial NCT04454411?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.